This week in General Medicine
Nov 16, 2026
Intensive Blood-Pressure Control in Patients with Previous Ischemic Stroke.
In 4368 Brazilian adults with prior ischemic stroke or TIA, a systolic target below 120 lowered major cardiovascular events by about a fifth versus below 140, with more renal events.
New England Journal of Medicine · 2026 · PubMed
This week’s highlights
Read the weekly briefing
This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.
This week: a lower blood pressure target cuts cardiovascular events after stroke, stopping statins in older adults meets a noninferiority bar, and two large cardiovascular drug trials fail despite deep biomarker reductions.
Welcome to This Week in General Medicine. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.
In the New England Journal of Medicine, Sampaio Silva and colleagues report OPTIMAL-STROKE, an open-label randomized trial at 30 sites in Brazil [1]. It enrolled 4368 adults with elevated blood pressure and a previous ischemic stroke or transient ischemic attack. Their average age was about 64, and just under half of participants were women. Patients were assigned to a systolic target below 120 or below 140. Achieved systolic pressure differed by about 13 points, settling near 122 in the intensive group and 135 in the standard group. Over a median of almost four years, the composite of cardiovascular death, nonfatal heart attack, nonfatal stroke, or hospitalization for unstable angina or heart failure occurred in about 11 percent of the intensive group and about 13 and a half percent of the standard group. That is a relative reduction of about a fifth. Serious adverse events overall were similar between groups. The renal composite, a sustained fall in filtration rate of at least fifty percent or progression to end-stage kidney disease, was more common with intensive treatment, and the abstract does not give those figures. The trial was open label and ran in a single country. It adds randomized evidence for a lower target in secondary stroke prevention, a group where the data had been uncertain.
The same Brazilian research group, with Santo as lead author and also in the New England Journal of Medicine, ran OPTIMAL-DIABETES with an identical design [2]. It enrolled 9476 ethnically diverse patients with type 2 diabetes and high cardiovascular risk, and about 62 percent of participants were women. Mean systolic pressure during follow-up was again around 122 in the intensive arm and 135 in the standard arm. Over four years, the same composite occurred in 6 percent of the intensive group and just under 7 percent of the standard group, a difference that was not statistically significant. Serious adverse events were close to 15 percent in both arms. The abstract does not report kidney outcomes. These two sister trials, with the same targets and the same investigators, reach different answers: a reduction in events after stroke and no significant reduction in diabetes. The overall event rate in the diabetes trial was low, which limits the ability to detect a modest effect, and the open-label design applies here as well. As evidence, it adds another null result to the long-running question of tight systolic targets in type 2 diabetes, and it sits in direct contrast with the stroke result.
In the New England Journal of Medicine, Rodondi and colleagues report STREAM, an international open-label noninferiority trial [3]. It enrolled 1880 adults aged 70 or older who were taking statins for primary prevention, had at least two chronic conditions, and had no known cardiovascular disease. Mean age was about 77. Participants were randomized to stop or continue lipid-lowering therapy. The primary measure was event-free survival time over two years for a composite of nonfatal heart attack, nonfatal ischemic stroke, or death from any cause. Stopping cost about two weeks of event-free time, which sat within the prespecified margin of just over five weeks, so discontinuation met noninferiority. The raw counts lean the other way numerically: about 13 percent of the discontinuation group had a primary event, compared with about 9 percent of the continuation group. Serious adverse events were also somewhat more frequent after stopping, at 43 versus 40 percent. The margin was chosen by the investigators, follow-up was only two years, and the design was open label. The trial adds randomized data on statin deprescribing in multimorbid older adults, though the numerical excess in events leaves room for differing interpretations of what noninferior means here.
Now, four in brief.
Two large trials aimed at newer cardiovascular targets, both in the New England Journal of Medicine, were negative. Cho and colleagues report Lp[a]HORIZON, an international placebo-controlled trial of monthly pelacarsen in 8350 patients with established cardiovascular disease and lipoprotein(a) of at least 70 milligrams per deciliter [4]. Pelacarsen produced a large fall in lipoprotein(a) at one year. Over almost five years, major adverse cardiovascular events occurred in about 12 percent of each arm, with no difference, and the result was the same among patients with levels of at least 90. Serious adverse events were slightly less frequent on the drug. This is large, blinded and clearly null outcome evidence.
Ridker and colleagues report ZEUS, a double-blind trial of the interleukin-6 antibody ziltivekimab in 6376 adults with atherosclerotic disease, chronic kidney disease, and a high-sensitivity C-reactive protein of at least 2 milligrams per liter [5]. The drug lowered C-reactive protein substantially. Over almost three years, major adverse cardiovascular events occurred in close to 18 percent of both arms, a null result. Serious infections were somewhat more frequent with ziltivekimab, at about 20 versus 18 percent. The abstract does not report kidney outcomes. Like the pelacarsen trial, this is firm, blinded, negative evidence that lowering the target biomarker did not lower events.
In the BMJ, Yang and colleagues report a double-blind, placebo-controlled trial at five hospitals in China in 2036 patients aged 60 to 80 who were taking an ACE inhibitor or angiotensin receptor blocker before non-cardiac surgery under general anaesthesia [6]. Omitting the morning dose reduced perioperative hypotension by about 14 percentage points, to about 31 percent, and fewer patients needed vasopressors. Thirty-day complications and mortality did not differ between groups. The design is rigorous and the authors describe the evidence as high certainty, though hypotension is a surrogate and the hard outcomes were secondary endpoints.
Also in the New England Journal of Medicine, Pellegrini and colleagues report PEPPER, a comparative-effectiveness trial in 18,883 patients undergoing hip or knee replacement, randomized to aspirin 81 milligrams twice daily, warfarin, or rivaroxaban 10 milligrams daily for 30 days [7]. Death or symptomatic venous thromboembolism occurred in about 1.3 percent with aspirin, 1.2 percent with warfarin and 0.9 percent with rivaroxaban. Aspirin did not meet noninferiority against either anticoagulant for effectiveness, and neither anticoagulant met noninferiority to aspirin for safety. Event rates were low and differences small, so the result is a trade-off between clot prevention and bleeding with no clear winner.
Three quick signals.
In Nature Medicine, Green and colleagues randomized 120 adults with overweight or obesity on tirzepatide to thrice-weekly resistance training or usual activity for 40 weeks [8]. Weight loss was similar, around 22 kilograms, but resistance training reduced lean mass loss by about one kilogram, and strength rose with training while it fell without. This is a small trial with body-composition endpoints.
In Annals of Internal Medicine, Winterstein and colleagues analysed two claims databases covering more than 200,000 pregnancies [9]. First-trimester doxycycline for respiratory infection was associated with roughly 35 to 55 percent higher risk of pregnancy loss than amoxicillin or macrolides, while acne findings were inconsistent between databases. The data are observational, with possible residual confounding and misclassification.
In JAMA, Albers and Heit review acute ischemic stroke treatment under the 2026 American Heart Association and American Stroke Association guidelines [10]. They describe intravenous thrombolysis within 4.5 hours, extendable with perfusion imaging in selected patients, and thrombectomy for large vessel occlusion up to 24 hours. It is a narrative review with no new data.
Stepping back across this week's papers, the clearest pattern is the gap between moving a biomarker and moving outcomes. Two large blinded trials produced deep reductions in their targets with no change in cardiovascular events. Two blood pressure trials with near-identical designs and similar achieved pressures reached different conclusions in different populations. Much of the week's positive evidence rests on open-label designs, surrogate endpoints, or a single country, which limits how far any one result can travel.
If you only have time for one paper this week, make it OPTIMAL-STROKE [1]. It provides randomized outcome evidence on a lower systolic target in secondary stroke prevention, a question that had stayed open, and its contrast with the diabetes trial reopens the question of which patients gain from tighter control.
That's your roundup for This Week in General Medicine. The full transcript and references are available on the episode page. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.
This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.
Get General Medicine every week
By email, Spotify, Apple or any podcast app.
Spot something worth flagging?